{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:44:22Z","timestamp":1761896662826},"reference-count":27,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.clinthera.2017.09.016","type":"journal-article","created":{"date-parts":[[2017,11,4]],"date-time":"2017-11-04T02:31:01Z","timestamp":1509762661000},"page":"2296-2310.e14","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Factors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries"],"prefix":"10.1016","volume":"39","author":[{"given":"Edith M.","family":"Heintjes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jetty A.","family":"Overbeek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian C.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Prieto-Alhambra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Lapi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Hammar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene D.","family":"Bezemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.09.016_bib1","series-title":"IDF Diabetes Atlas","year":"2015"},{"key":"10.1016\/j.clinthera.2017.09.016_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00125-008-1157-y","article-title":"Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes","volume":"52","author":"Nathan","year":"2009","journal-title":"Diabetologia"},{"issue":"9 Suppl 1","key":"10.1016\/j.clinthera.2017.09.016_bib3","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.amjmed.2013.06.009","article-title":"Options for combination therapy in type 2 diabetes: comparison of the ADA\/EASD position statement and AACE\/ACE algorithm","volume":"126","author":"Bailey","year":"2013","journal-title":"The American journal of medicine"},{"key":"10.1016\/j.clinthera.2017.09.016_bib4","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes care"},{"key":"10.1016\/j.clinthera.2017.09.016_bib5","first-page":"137","article-title":"NHG-Standaard Diabetes mellitus type 2 (Tweede herziening)","volume":"49","author":"Rutten","year":"2006","journal-title":"Huisarts Wet"},{"key":"10.1016\/j.clinthera.2017.09.016_bib6","article-title":"National Collaborating Centre for Chronic Conditions and the Centre for Clinical Practice at NICE","year":"2009","journal-title":"NICE guideline Type 2 diabetes: The management of type 2 diabetes"},{"key":"10.1016\/j.clinthera.2017.09.016_bib7","unstructured":"Ariz Arnedo MJ, Artola Men\u00e9ndez S, Barutell Rubio L, et al. Pr\u00e1ctica cl\u00ednica en la DM2 (Clinical practice in type 2 diabetes). Barcelona, 2011."},{"key":"10.1016\/j.clinthera.2017.09.016_bib8","unstructured":"Societa Italiana di Diabetologia (SID) Associazione Medici Diabetologi (AMD) Standard italiani per la cura del diabete mellito tipe 2 (SIdD). Standard Italiani per la cura del diabete mellito tipo 2 (Italian guideline for treating T2DM), 2011. http:\/\/www.aemmedi.it\/files\/Linee-guida_Raccomandazioni\/2011\/AMD_SID_SIMMG_2011.pdf."},{"key":"10.1016\/j.clinthera.2017.09.016_bib9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ijcp.12251","article-title":"Glycaemic control and implementation of the ADA\/EASD-2006 consensus algorithm in type 2 diabetes mellitus patients in primary care in Spain","volume":"68","author":"Alvarez-Guisasola","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinthera.2017.09.016_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.diabres.2011.05.004","article-title":"Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy's Lombardy Region: a large population-based study","volume":"93","author":"Baviera","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clinthera.2017.09.016_bib11","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.clinthera.2017.02.008","article-title":"Type 2 Diabetes mellitus treatment patterns across Europe: a population-based multi-database study","volume":"39","author":"Overbeek","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2017.09.016_bib12","unstructured":"Pharmo Institute for Drug Outcomes Research. 2016. http:\/\/www.pharmo.com. Accessed April 22, 2016."},{"key":"10.1016\/j.clinthera.2017.09.016_bib13","first-page":"135","article-title":"Construction and validation of a scoring system for the selection of high-quality data in a Spanish Population Primary Care Database (SIDIAP)","volume":"19","author":"Garcia-Gil Mdel","year":"2011","journal-title":"Inform Prim Care"},{"key":"10.1016\/j.clinthera.2017.09.016_bib14","doi-asserted-by":"crossref","first-page":"774","DOI":"10.2337\/dc11-1679","article-title":"Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain)","volume":"35","author":"Vinagre","year":"2012","journal-title":"Diabetes care"},{"key":"10.1016\/j.clinthera.2017.09.016_bib15","year":"2015","journal-title":"The Health Improvement Network (THIN) database"},{"key":"10.1016\/j.clinthera.2017.09.016_bib16","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified Poisson regression approach to prospective studies with binary data","volume":"159","author":"Zou","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clinthera.2017.09.016_bib17","doi-asserted-by":"crossref","first-page":"A600","DOI":"10.1016\/j.jval.2015.09.2057","article-title":"Factors associated with T2DM treatment choice across Europe","volume":"18","author":"Overbeek","year":"2015","journal-title":"Value health"},{"key":"10.1016\/j.clinthera.2017.09.016_bib18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1472-6823-14-73","article-title":"Antihyperglycaemic treatment patterns, observed glycaemic control and determinants of treatment change among patients with type 2 diabetes in the United Kingdom primary care: a retrospective cohort study","volume":"14","author":"Maguire","year":"2014","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.clinthera.2017.09.016_bib19","author":"Verduijn","year":"2010","journal-title":"NHG-Standpunt DPP-4-remmers en GLP-1-agonisten"},{"key":"10.1016\/j.clinthera.2017.09.016_bib20","unstructured":"Medicijnbalans. GLP-1-agonists. Reimbursement. Editor: Institute for responsible medication use. https:\/\/www.medicijnbalans.nl\/medicijngroepen\/glp-1-agonisten\/vergoeding. Last updated October 2017"},{"key":"10.1016\/j.clinthera.2017.09.016_bib21","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2125.2012.04401.x","article-title":"Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone","volume":"75","author":"Leal","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2017.09.016_bib22","doi-asserted-by":"crossref","first-page":"b4731","DOI":"10.1136\/bmj.b4731","article-title":"Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database","volume":"339","author":"Tzoulaki","year":"2009","journal-title":"BMJ (Clinical research edition)"},{"issue":"3","key":"10.1016\/j.clinthera.2017.09.016_bib23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00003495-200565030-00005","article-title":"Oral antidiabetic agents: current role in type 2 diabetes mellitus","volume":"65","author":"Krentz","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2017.09.016_bib24","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1463-1326.2010.01212.x","article-title":"Pharmacokinetics of dipeptidylpeptidase-4 inhibitors","volume":"12","author":"Scheen","year":"2010","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.clinthera.2017.09.016_bib25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/00325481.2016.1191955","article-title":"Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile","volume":"128","author":"Schwartz","year":"2016","journal-title":"Postgrad Med"},{"key":"10.1016\/j.clinthera.2017.09.016_bib26","unstructured":"Verduijn T, Janssen PG. NHG-Standpunt DPP-4-remmers en GLP-1-agonisten. Utrecht2010 [April 22, 2016]; Available from: http:\/\/www.diabetes2.nl\/uploads\/user\/rest\/DPP-4-remmers_en_GLP-1-agonisten.pdf. (translation: NHG position statement on DPP-4-inhibitors and GLP-1-agonists)."},{"issue":"12","key":"10.1016\/j.clinthera.2017.09.016_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11883-016-0633-y","article-title":"4. Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet","volume":"18","author":"Flory","year":"2016","journal-title":"Curr Atheroscler Rep"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817310032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817310032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T17:03:32Z","timestamp":1530205412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817310032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0149291817310032"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.09.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}